Table of Content

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study

3. Executive Summary

4. Market Dynamics
4.1. Market Overview
4.2. Drivers
4.2.1. Government Initiatives Supporting Africa’s Healthcare Sector
4.2.2. Rising Prevalence of Communicable and Noncommunicable Diseases
4.2.3. Key Market Players’ Increasing Investments in Africa’s IVD Sector
4.3. Restraints
4.3.1. High Prices of IVD Products
4.4. Opportunities
4.4.1. Increasing Awareness About the Importance of Early Diagnosis
4.5. Challenges
4.5.1. Uneven Access to Healthcare
4.5.2. Shortage of Trained Healthcare Personnel

5. Africa IVD Market, by Product Category
5.1. Introduction
5.2. Reagents, Assays, and Kits
5.3. Instruments
5.4. Software & Services

6. Africa IVD Market, by Technology
6.1. Introduction
6.2. Immunoassay
6.3. Whole Blood Glucose Monitoring
6.4. Point-of-Care Diagnostics
6.5. Clinical Chemistry
6.6. Molecular Diagnostics
6.7. Hematology
6.8. Coagulation & Hemostasis
6.9. Critical Care
6.10. Urinalysis
6.11. Other IVD Technologies

7. Africa IVD Market, by Application
7.1. Introduction
7.2. Infectious Diseases
7.3. Oncology
7.4. Diabetes
7.5. Endocrinology
7.6. Cardiology
7.7. Other Applications

8. Africa IVD Market, by Diagnostic Approach
8.1. Introduction
8.2. Laboratory Testing
8.3. Point-of-Care Testing
8.4. OTC/Self-Testing

9. Africa In Vitro Diagnostics Market, by Customer Type
9.1. Introduction
9.2. Hospital Labs
9.3. Private Labs
9.4. Home Care/Self-Testing
9.5. Government
9.6. Other Customer Types

10. Africa IVD Market, by Geography
10.1. Introduction
10.2. South Africa
10.3. Egypt
10.4. Nigeria
10.5. Kenya
10.6. Algeria
10.7. Tanzania
10.8. Morocco
10.9. Tunisia
10.10. Rest of Africa

11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2021)
11.4.1. F. Hoffmann-La Roche Ltd (Switzerland)
11.4.2. Abbott Laboratories (U.S.)
11.4.3. Danaher Corporation (U.S.)

12. Company Profiles (Business Overview, Financial Overview, Solutions Portfolio, Strategic Developments)
12.1. Abbott Laboratories
12.2. Becton, Dickinson and Company
12.3. bioM?rieux SA
12.4. Danaher Corporation
12.5. F. Hoffmann-La Roche Ltd
12.6. QIAGEN N.V.
12.7. Siemens Healthineers AG (Subsidiary of Siemens AG)
12.8. Thermo Fisher Scientific Inc.
12.9. Bio-Rad Laboratories, Inc.
12.10. Illumina, Inc.
12.11. Shenzhen Mindray Bio-Medical Electronics Co., Ltd

13. Appendix
13.1. Questionnaire



List of Figures

List of Figures

Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Africa IVD Market, by Product Category, 2022 Vs. 2029 (USD Million)
Figure 8 Africa IVD Market, by Technology, 2022 Vs. 2029 (USD Million)
Figure 9 Africa IVD Market, by Application, 2022 Vs. 2029 (USD Million)
Figure 10 Africa IVD Market, by Diagnostic Approach, 2022 Vs. 2029 (USD Million)
Figure 11 Africa IVD Market, by Customer Type, 2022 Vs. 2029 (USD Million)
Figure 12 Africa IVD Market, by Geography, 2022 Vs. 2029 (USD Million)
Figure 13 Market Dynamics
Figure 14 Africa IVD Market Size, by Product Category, 2022 Vs. 2029 (USD Million)
Figure 15 Africa IVD Market, by Technology, 2022 Vs. 2029 (USD Million)
Figure 16 Adult Population (20–79 Years) with Diabetes in African Countries (Millions)
Figure 17 Africa IVD Market Size, by Application, 2022 Vs. 2029 (USD Million)
Figure 18 Number of HIV Cases Vs. HIV/AIDS Deaths in African Countries (2020)
Figure 19 Africa IVD Market Size, by Diagnostic Approach, 2022 Vs. 2029 (USD Million)
Figure 20 Africa in Vitro Diagnostics Market Size, by Customer Type, 2022 Vs. 2029 (USD Million)
Figure 21 Africa: Number of People (Aged 20–79 Years) with Diabetes (in Millions), 2021–2045
Figure 22 Africa IVD Market, by Snapshot, 20222–2029 (USD Million)
Figure 23 South Africa: Number of People (All Ages) Living with HIV (2010–2020)
Figure 24 South Africa: Number of People with Diabetes (in Thousands), 2000–2045
Figure 25 Nigeria: Number of PMI-Supported Health Facilities (2016–2020)
Figure 26 Algeria: Population Aged 65 and Above (2015–2021)
Figure 27 Algeria: People Aged 20-79 Years who have Diabetes (2011–2045) (in Thousands)
Figure 28 Tanzania: Number of People with HIV (2010–2020)
Figure 29 Tanzania: Number of Adults (20–79 Years) with Diabetes (2011–2021)
Figure 30 Morocco: Number of New Cancer Cases: 2020-2030
Figure 31 Share of People Living in Urban Areas: 2015–2020
Figure 32 Public Expenditure on Healthcare as Percent of Total Healthcare Expenditure: 2015 -2019
Figure 33 Key Growth Strategies Adopted by Leading Players (2019–2022)
Figure 34 Africa IVD Market: Competitive Benchmarking
Figure 35 Market Share Analysis: Africa IVD Industry (2021)
Figure 36 Abbott Laboratories: Financial Overview (2019–2021)
Figure 37 Becton, Dickinson, and Company: Financial Overview (2019–2021)
Figure 38 bioM?rieux SA: Financial Overview, (2019–2021)
Figure 39 Danaher Corporation: Financial Overview (2019–2021)
Figure 40 F. Hoffman-La Roche Ltd.: Financial Overview (2019–2021)
Figure 41 QIAGEN N.V.: Financial Overview (2019–2021)
Figure 42 Siemens Healthineers AG: Financial Overview (2019–2021)
Figure 43 Thermo Fisher Scientific Inc.: Financial Overview (2019–2021)
Figure 44 Bio-Rad Laboratories: Financial Overview (2019–2021)
Figure 45 Illumina, Inc.: Financial Overview (2019–2021)
Figure 46 Shenzhen Mindray Bio-Medical Electronics Co., Ltd: Financial Overview (2019–2021)